SOURCE-LINKED STUDY SUMMARY
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind placebo-controlled trial randomized adults after successful intensive lifestyle weight loss to weekly tirzepatide or placebo.
- Who / model studied
- Adults had overweight or obesity with an obesity-related complication, no diabetes, and prior successful weight loss during intensive lifestyle intervention.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Tirzepatide produced substantial additional weight loss and more participants reached the additional weight-loss threshold than with placebo.
- Limitations & context
- Gastrointestinal events were the most common adverse events, although most were mild to moderate.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-023-02597-w